Make every move count

Solutions for Financial Services

Where Strategic Insight Meets Investment Success

In today’s financial landscape, your success hinges on the ability to make smarter, faster, and more strategic decisions. Our solutions are purpose-built to empower both sell-side and buy-side leaders like you to navigate the complexities of the Pharma investment and planning cycle with confidence and clarity.

The Challenge

Overestimating or underestimating market demand

Inaccurate revenue projections

Failure to identify and quantify risks

Incorrect prioritization of pipeline assets

Missed high impact events

Delayed response to portfolio moves

Overevaluation or undervaluation of assets

Failure to identify investment opportunities

Insufficient resources

The Result

Strategic Blind Spots

Misjudging market demand, misprioritizing pipeline assets, or missing high-impact events might lead to underperformance of key products, loss of market share, and diminished long-term value creation.

Capital Misallocation

Inaccurate revenue forecasts, asset misvaluation, and overlooked investment opportunities can result in inefficient use of capital, inflated valuations, and weakened investor returns.

Execution Risk

Delayed portfolio decisions, unaddressed risks, and resource constraints can cause regulatory delays, missed launch windows, and increased operational costs, all of which erode investor confidence.

The Solution:
How We Support You

We support financial services professionals at every stage of the investment journey in biopharma.

Opportunity Sizing
Diligence & Valuation
Portfolio Optimization
Market Monitoring

Size the Opportunity

Quantify total and addressable market size for a therapy or technology

Model adoption and uptake curves to inform revenue projections

Identify high-growth indications and geographies to guide investment focus

Build accurate, defensible revenue forecasts

using historical performance trends and forward-looking market analytics tailored to financial planning cycles

Maintain dynamic visibility into market drivers

with regularly updated insights that inform budget adjustments, risk mitigation, and growth projections

Stress-test financial assumptions

with scenario modeling to evaluate the impact of competitive events, regulatory shifts, and pipeline changes on revenue outlook

Enhance market sizing precision

to support valuation models and investment decisions, incorporating variables like disease prevalence, access dynamics, and innovation pipelines

Power Valuation and Investment Decisions

Accelerate due diligence by integrating clinical, commercial, and competitive intelligence

Benchmark licensing and acquisition deals to support data-driven valuations

Inform investment theses with comparable deal insights and asset performance data

Strengthen deal assessments with data-driven valuations, market benchmarks, and insights into upcoming clinical and regulatory milestones.

Identify high-value investment opportunities

by tracking innovation trends, pipeline activity, and competitor movements to align external investments with financial growth objectives

Accelerate due diligence and valuation modeling

with structured, data-backed insights into deal terms, asset forecasts, and market context to assess ROI and mitigate risk

Strengthen negotiation positions

with detailed intelligence on financial benchmarks, licensing structures, and company portfolios to secure favorable economics and protect long-term value

Evaluate licensing deal performance against market

comparables to ensure alignment with financial expectations and maximize the strategic return of each investment

Optimize Portfolio for Value and Growth

Identify asset overlap or diversification to assess portfolio balance

Evaluate risk exposure across therapeutic areas and development stages

Prioritize investments based on strategic fit and long-term value

Inform investment decisions with a comprehensive view of commercial potential, development progress, and portfolio risk.

Gain real-time portfolio visibility

by integrating financial, clinical, and regulatory insights to assess asset value and inform capital allocation decisions

Prioritize high-impact investments

by evaluating market opportunity, trial progress, and competitive dynamics to focus resources on the most promising assets

Support strategic planning

with predictive modeling that forecasts asset performance under varying market and regulatory scenarios

Improve cross-functional alignment

through transparent, data-driven reports that centralize insights and streamline investment decision-making across teams

Monitor the Market for Financial Agility

Track clinical milestones, regulatory decisions, and market shifts that influence asset valuation and stock performance

Monitor key events and catalysts that drive investor interest or trigger deal activity

Stay ahead of competitors by anticipating high-impact developments across the landscape

Stay ahead of market shifts with timely insights into competitor pipelines, commercial performance, and industry trends.

Stay ahead of the market

by monitoring competitor activities in real time—tracking trials, approvals, partnerships, and launches to assess financial impact and timing risks

Assess competitor positioning and market threats

using data on product lifecycles, development pipelines, and commercial strategies to support revenue planning and defend market share

Drive informed decisions across finance and strategy

with centralized, data-backed competitive intelligence that ensures alignment and confidence in forecasting, M&A, and investment prioritization

With the perfect blend of forecast data, competitive intelligence, and strategic insight, our solutions don’t just support decisions—they elevate them.

Make every move count. Let’s build your next advantage.

Featured Report:

2025 World Preview: Financial Services Edition

As global pharmaceutical players navigate economic headwinds and regulatory shifts, this year’s World Preview discusses the data and insights shaping the next decade of life sciences investment.

From the meteoric rise of GLP-1s to China’s growing influence and the looming patent cliff, our flagship report highlights the forces reshaping the industry through 2030.

Related Resources

Lead with Intelligence. Invest with Confidence.

Let’s build your next advantage.

I would like to receive Evaluate industry & market reports, and the latest news from Evaluate. エバリュエートの業界・市場レポートやイベント等最新ニュースを受け取る（無料）

Connect with our advisory team
Get insights on BD&L, portfolio, and competitive intelligence 業界特化型コンサルタントとの個別相談を希望する
BD&L／ポートフォリオ／競合インテリジェンスについて、担当者よりご連絡いたします

Your information will be used in accordance with our Privacy notice. ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。

Core Forecasting Products

Regional Forecasts

Forecast Enablement

Bespoke Forecasting

Portfolio & Scenario Analysis

Competitive Context

Pipeline & Asset Intelligence

Deal and Asset Evaluation

Bespoke Business Development Analysis

Scientific & Pipeline Intelligence

Competitive Intelligence Platforms

Epidemiology Context

Market and Company Benchmarks

Custom Solutions

Support

Training and Enablement

Need Help?

Forecasting

Business Development & Licensing

Portfolio Strategy

Competitive Intelligence

Discover Resources

Make every move count

Solutions for Financial Services

Where Strategic Insight Meets Investment Success

The Challenge